- Drugmakers seek replacements for expiring cardio blockbusters
Expiring patents for best-selling cardiovascular drugs, including Bristol-Myers Squibb and Sanofi's anti-clotting drug Plavix and Pfizer's cholesterol-lowering treatment Lipitor, have left drugmakers scrambling for next-generation replacements. The patent losses could drag down sales of cardiovascular drugs to $60 billion by 2017 from $83 billion last year, according to analysts' forecasts. Reuters (8/29)        | Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenge's faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio. | |
| Health Care & Policy |  |  | | - FDA panel supports use of Abbott's Humira for ulcerative colitis
An FDA advisory panel recommended approval of Abbott Laboratories' Humira as a treatment for ulcerative colitis, saying that the drug's benefits surpass its risks. Humira already is cleared for six other indications, including Crohn's disease and rheumatoid arthritis. The FDA is expected to complete its review this year. Reuters (8/28) - Kyowa halts late-stage trial of ArQule's lung cancer drug tivantinib
ArQule said partner Kyowa Hakko Kirin ceased enrollment in a Phase III trial of experimental lung cancer drug tivantinib because of suspected cases of interstitial lung disease. The study is evaluating the efficacy of tivantinib combined with Roche Holding's Tarceva, or erlotinib, against a combination of Tarceva and placebo in treating patients with nonsquamous nonsmall-cell lung cancer. The suspension likely won't affect other trials of tivantinib, analysts said. Reuters (8/29) - Researchers grow sperm cells from skin cells
U.S. researchers have induced early-stage sperm cells from adult skin cells. The development indicates that it may be possible to grow human sperm from induced pluripotent stem cells, a researcher said. The method has the potential to lead to advances that address infertility and help cancer survivors become fathers. The Telegraph (London) (8/29)  | Get More with The Business Platinum Card from American Express OPEN. EARN 25,000 MEMBERSHIP REWARDS® POINTS by spending $5,000 in the first 3 months of Card membership†.
PLUS GET 40+ PREMIUM BENEFITS:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any Airline
• 24/7 personal concierge
LEARN MORE †Terms and Restrictions Apply. |
  | Company & Financial News | | | | | Industry Deals | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | - Researchers report findings of cotton genome-sequencing project
An international team of researchers announced that they have sequenced and have begun comparing the genomes of Gossypium raimondii, a wild South American cotton species, with previously sequenced plants and they found that the cotton, like cacao plants, has a family of CDN1 genes that play a role in the production of a compound used to drive away some herbivores and potential pathogens. The project will "provide a major source of candidate genes important for the genetic improvement of cotton quality and productivity," said researchers from the Chinese Academy of Agricultural Sciences' Cotton Research Institute. GenomeWeb Daily News (free registration) (8/27) | Industrial & Environmental | | | | - Calls for RFS waiver could drive away investors, BIO exec says
Calls from a group of governors for a temporary suspension of the Renewable Fuel Standard is sending a negative signal to investors in advanced biofuels, according to biofuel groups during a conference call Tuesday. "I think just the fact that people are filing waivers kind of creates turbulence in the system," said BIO executive vice president Brent Erickson. The Hill/E2 Wire blog (8/28) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | I'll walk where my own nature would be leading: It vexes me to choose another guide."
--Emily Brontë,
British novelist and poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, August 29, 2012
- Tuesday, August 28, 2012
- Monday, August 27, 2012
- Friday, August 24, 2012
- Thursday, August 23, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment